close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biotricity, Inc. - Common Stock (NQ:BTCY)

0.4631 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biotricity, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Biotricity Completes Nasdaq Listing ↗
Closes $15 Million Underwritten Public Offering REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 / Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostic and consumer... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week ↗
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week ↗
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (... 
Via Benzinga
News headline image
Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market ↗
REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 / Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced... 
Via Benzinga
News headline image
Who is Dr. Waqaas Al-Siddiq, and Why are His Wearables the Most Crucial Devices MedTech Has Ever Seen? ↗
Biotricity Inc. (NASDAQ: BTCY) is a medtech startup that has seen quarter-over-quarter (QoQ) growth since its inception within the cardiac arena, and just listed on the NASDAQ as... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Innovative Company Biotricity is Providing Solutions for Chronic Diseases ↗
A new study revealed that 44% of older millennials that will soon hit 40 suffer at least one chronic health condition that takes a toll, both financially and emotionally —... 
Via Benzinga
News headline image
Healthy Hearts and Healthy Wallets: Why one Healthtech Startup is a Must-Invest ↗
Last month, we saw a lot of great startups at the Benzinga Global Small Cap Conference. Many of them screamed, “This is an innovation tech stock you need to buy now!... 
Via Benzinga
News headline image
Why A Northstar Analyst Is Bullish On This Disruptive MedTech Company ↗
A strong value proposition and high retention rate have turned Northland Capital Markets bullish on Biotricity, Inc (OTC: 
Via Benzinga
News headline image
Lasting Impact of Covid: Fewer Doctor's Office Visits Thanks to At-Home Diagnostics ↗
While treatment has long been viewed as the central role of our healthcare system, the COVID-19 pandemic brought diagnostics to center stage. Early and accurate detection was... 
Via Benzinga
News headline image
Maxim Group Is Bullish About Biotricity Generating Over 100% Revenue Growth ↗
Biotricity Inc (OTC: BTCY) has a multi-billion dollar target addressable market, which should expand as an ecosystem is created for solutions to chronic conditions, according to... 
Via Benzinga
News headline image
Remote Monitoring Telemedicine Company Sees Spiked Growth Of Products And Technology ↗
The following article is sponsored by Biotricity Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today